Neurocrine Biosciences (NBIX) Receivables - Other (2019 - 2025)

Neurocrine Biosciences' Receivables - Other history runs 7 years deep, the most recent figure standing at $20.5 million for Q4 2025.

• Quarterly Receivables - Other rose 42.36% year-over-year to $20.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.5 million (up 42.36% YoY) and the FY2025 annual result came in at $20.5 million, up 42.36% from the prior year.
• Receivables - Other was $20.5 million for Q4 2025 at Neurocrine Biosciences, up from $14.4 million in the prior quarter.
• Across five years, Receivables - Other topped out at $20.5 million in Q4 2025 and bottomed at $2.2 million in Q4 2021.
• A 5-year average of $6.8 million and a median of $4.4 million in 2023 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other plunged 40.54% — and 2024, when it jumped 186.36%.
• Neurocrine Biosciences' Receivables - Other stood at $2.2 million in 2021, then surged by 113.64% to $4.7 million in 2022, then jumped by 138.3% to $11.2 million in 2023, then climbed by 28.57% to $14.4 million in 2024, then surged by 42.36% to $20.5 million in 2025.
• Business Quant data shows NBIX's Receivables - Other at $20.5 million in Q4 2025, $14.4 million in Q4 2024, and $12.6 million in Q1 2024.